Rational formulation engineering of fraxinellone utilizing 6-O-α-D-maltosyl-β-cyclodextrin for enhanced oral bioavailability and hepatic fibrosis therapy

Rational formulation engineering of fraxinellone utilizing 6-O-α-D-maltosyl-β-cyclodextrin for enhanced oral bioavailability and hepatic fibrosis therapy

Although Fraxinellone (Frax) isolated from Dictamnus albus L. possessed excellent anti-hepatic fibrosis activity, oral administration of Frax suffered from the inefficient therapeutic outcome in vivo due to negligible oral absorption. At present, the oral formulation of Frax is rarely exploited. For...

Full description

Bibliographic Details
Main Authors: Jianbo Li, Tiange Feng, Weijing Yang, Yaru Xu, Shuaishuai Wang, Huijie Cai, Zhilei Liu, Hong Qiang, Jinjie Zhang
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Drug Delivery
Subjects:
fraxinellone
cyclodextrin derivatives
oral bioavailability
solubility
hepatic fibrosis
Online Access:http://dx.doi.org/10.1080/10717544.2021.1976310

Similar Items

Similar Items